Exagen (XGN) Stock Price
Exagen Price
Revenue has compounded at 38.9% per year over the past 13 years to 66.58 M USD. Exagen's net margin stands at -30.0%, up from -55.6% several years earlier. Analysts set a median price target of 15.30 USD, implying 237.7% above the current price. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 71% above its 52-week low.
Exagen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Exagen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Exagen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Exagen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Exagen Price |
|---|---|
| 7/31/2026 | 4.53 USD |
| 7/30/2026 | 4.67 USD |
| 7/29/2026 | 4.42 USD |
| 7/27/2026 | 4.40 USD |
| 7/23/2026 | 4.95 USD |
| 7/22/2026 | 4.94 USD |
| 7/21/2026 | 4.86 USD |
| 7/20/2026 | 4.68 USD |
| 7/17/2026 | 4.39 USD |
| 7/16/2026 | 4.25 USD |
| 7/15/2026 | 4.30 USD |
| 7/14/2026 | 4.09 USD |
| 7/13/2026 | 4.25 USD |
| 7/10/2026 | 4.45 USD |
| 7/9/2026 | 4.62 USD |
| 7/8/2026 | 4.42 USD |
| 7/7/2026 | 4.80 USD |
| 7/6/2026 | 4.48 USD |
| 7/2/2026 | 4.54 USD |
| 7/1/2026 | 4.71 USD |
| 6/30/2026 | 4.65 USD |
| 6/29/2026 | 4.75 USD |
| 6/26/2026 | 4.58 USD |
| 6/25/2026 | 4.64 USD |
| 6/24/2026 | 4.52 USD |
| 6/23/2026 | 4.36 USD |
| 6/22/2026 | 4.32 USD |
| 6/18/2026 | 4.54 USD |
| 6/17/2026 | 4.25 USD |
| 6/16/2026 | 4.55 USD |
| 6/15/2026 | 4.57 USD |
| 6/12/2026 | 4.67 USD |
| 6/11/2026 | 4.48 USD |
| 6/10/2026 | 4.19 USD |
| 6/9/2026 | 4.31 USD |
| 6/8/2026 | 4.20 USD |
| 6/5/2026 | 4.29 USD |
| 6/4/2026 | 4.79 USD |
| 6/3/2026 | 4.54 USD |
| 6/2/2026 | 4.82 USD |
| 6/1/2026 | 5.35 USD |
| 5/29/2026 | 4.98 USD |
| 5/28/2026 | 5.08 USD |
| 5/27/2026 | 5.01 USD |
| 5/26/2026 | 4.62 USD |
| 5/22/2026 | 4.26 USD |
| 5/21/2026 | 4.27 USD |
| 5/20/2026 | 3.83 USD |
| 5/19/2026 | 3.73 USD |
| 5/18/2026 | 3.49 USD |
| 5/15/2026 | 3.64 USD |
| 5/14/2026 | 3.85 USD |
| 5/13/2026 | 3.47 USD |
| 5/12/2026 | 3.71 USD |
| 5/11/2026 | 3.98 USD |
| 5/8/2026 | 2.95 USD |
| 5/7/2026 | 2.94 USD |
| 5/6/2026 | 3.09 USD |
| 5/5/2026 | 3.09 USD |
| 5/4/2026 | 3.10 USD |
| 5/1/2026 | 3.06 USD |
| 4/30/2026 | 2.90 USD |
| 4/29/2026 | 2.76 USD |
| 4/28/2026 | 2.73 USD |
| 4/27/2026 | 2.74 USD |
| 4/24/2026 | 2.70 USD |
| 4/23/2026 | 2.70 USD |
| 4/22/2026 | 2.87 USD |
| 4/21/2026 | 2.91 USD |
| 4/20/2026 | 2.99 USD |
| 4/17/2026 | 3.08 USD |
| 4/16/2026 | 3.05 USD |
| 4/15/2026 | 3.07 USD |
| 4/14/2026 | 3.04 USD |
| 4/13/2026 | 2.97 USD |
| 4/10/2026 | 3.03 USD |
| 4/9/2026 | 3.09 USD |
| 4/8/2026 | 3.08 USD |
| 4/7/2026 | 3.00 USD |
| 4/6/2026 | 3.08 USD |
| 4/2/2026 | 3.06 USD |
| 4/1/2026 | 3.01 USD |
| 3/31/2026 | 3.00 USD |
| 3/30/2026 | 2.65 USD |
| 3/27/2026 | 2.68 USD |
| 3/26/2026 | 2.79 USD |
| 3/25/2026 | 2.88 USD |
| 3/24/2026 | 2.74 USD |
| 3/23/2026 | 2.85 USD |
| 3/20/2026 | 2.78 USD |
| 3/19/2026 | 2.97 USD |
| 3/18/2026 | 3.02 USD |
| 3/17/2026 | 3.17 USD |
| 3/16/2026 | 3.16 USD |
| 3/13/2026 | 3.07 USD |
| 3/12/2026 | 3.16 USD |
| 3/11/2026 | 3.11 USD |
| 3/10/2026 | 3.25 USD |
| 3/9/2026 | 3.38 USD |
| 3/6/2026 | 3.29 USD |
| 3/5/2026 | 3.22 USD |
| 3/4/2026 | 3.59 USD |
| 3/3/2026 | 3.43 USD |
| 3/2/2026 | 3.55 USD |
| 2/27/2026 | 3.62 USD |
| 2/26/2026 | 3.80 USD |
| 2/25/2026 | 3.80 USD |
| 2/24/2026 | 3.69 USD |
| 2/23/2026 | 3.70 USD |
| 2/20/2026 | 3.41 USD |
| 2/19/2026 | 3.27 USD |
| 2/18/2026 | 3.28 USD |
| 2/17/2026 | 3.31 USD |
| 2/13/2026 | 3.28 USD |
| 2/12/2026 | 3.24 USD |
| 2/11/2026 | 3.30 USD |
| 2/10/2026 | 3.50 USD |
| 2/9/2026 | 3.37 USD |
| 2/6/2026 | 3.51 USD |
| 2/5/2026 | 3.36 USD |
| 2/4/2026 | 3.51 USD |
| 2/3/2026 | 3.71 USD |
| 2/2/2026 | 3.83 USD |
| 1/30/2026 | 3.68 USD |
| 1/29/2026 | 3.95 USD |
| 1/28/2026 | 4.06 USD |
| 1/27/2026 | 4.31 USD |
| 1/26/2026 | 4.41 USD |
| 1/23/2026 | 4.60 USD |
| 1/22/2026 | 4.89 USD |
| 1/21/2026 | 4.73 USD |
| 1/20/2026 | 4.74 USD |
| 1/16/2026 | 4.69 USD |
| 1/15/2026 | 4.83 USD |
| 1/14/2026 | 5.09 USD |
| 1/13/2026 | 5.15 USD |
| 1/12/2026 | 5.95 USD |
| 1/9/2026 | 6.34 USD |
| 1/8/2026 | 6.17 USD |
| 1/7/2026 | 6.02 USD |
| 1/6/2026 | 6.09 USD |
| 1/5/2026 | 5.95 USD |
| 1/2/2026 | 6.04 USD |
| 12/31/2025 | 6.08 USD |
| 12/30/2025 | 6.01 USD |
| 12/29/2025 | 5.98 USD |
| 12/26/2025 | 6.13 USD |
| 12/24/2025 | 6.19 USD |
| 12/23/2025 | 6.32 USD |
| 12/22/2025 | 6.63 USD |
| 12/19/2025 | 6.43 USD |
| 12/18/2025 | 6.47 USD |
| 12/17/2025 | 6.41 USD |
| 12/16/2025 | 6.75 USD |
| 12/15/2025 | 7.03 USD |
| 12/12/2025 | 7.11 USD |
| 12/11/2025 | 7.21 USD |
| 12/10/2025 | 7.14 USD |
| 12/9/2025 | 7.02 USD |
| 12/8/2025 | 6.99 USD |
| 12/5/2025 | 7.20 USD |
| 12/4/2025 | 7.49 USD |
| 12/3/2025 | 7.28 USD |
| 12/2/2025 | 7.10 USD |
| 12/1/2025 | 7.50 USD |
| 11/28/2025 | 7.90 USD |
| 11/26/2025 | 7.74 USD |
| 11/25/2025 | 7.70 USD |
| 11/24/2025 | 7.56 USD |
| 11/21/2025 | 7.61 USD |
| 11/20/2025 | 7.77 USD |
| 11/19/2025 | 7.91 USD |
| 11/18/2025 | 8.21 USD |
| 11/17/2025 | 8.47 USD |
| 11/14/2025 | 9.01 USD |
| 11/13/2025 | 9.35 USD |
| 11/12/2025 | 9.59 USD |
| 11/11/2025 | 9.22 USD |
| 11/10/2025 | 9.46 USD |
| 11/7/2025 | 9.56 USD |
| 11/6/2025 | 10.38 USD |
| 11/5/2025 | 10.33 USD |
| 11/4/2025 | 10.77 USD |
| 11/3/2025 | 11.83 USD |
| 10/31/2025 | 11.67 USD |
| 10/30/2025 | 11.76 USD |
| 10/29/2025 | 11.85 USD |
| 10/28/2025 | 11.89 USD |
| 10/27/2025 | 11.91 USD |
| 10/24/2025 | 11.96 USD |
| 10/23/2025 | 11.92 USD |
| 10/22/2025 | 11.75 USD |
| 10/21/2025 | 11.69 USD |
| 10/20/2025 | 11.72 USD |
| 10/17/2025 | 11.54 USD |
| 10/16/2025 | 11.77 USD |
| 10/15/2025 | 11.92 USD |
| 10/14/2025 | 11.54 USD |
| 10/13/2025 | 11.04 USD |
| 10/10/2025 | 10.95 USD |
| 10/9/2025 | 11.08 USD |
| 10/8/2025 | 10.98 USD |
| 10/7/2025 | 10.96 USD |
| 10/6/2025 | 10.90 USD |
| 10/3/2025 | 10.96 USD |
| 10/2/2025 | 10.89 USD |
| 10/1/2025 | 10.98 USD |
| 9/30/2025 | 10.99 USD |
| 9/29/2025 | 10.77 USD |
| 9/26/2025 | 10.89 USD |
| 9/25/2025 | 10.57 USD |
| 9/24/2025 | 10.78 USD |
| 9/23/2025 | 9.92 USD |
| 9/22/2025 | 9.85 USD |
| 9/19/2025 | 9.56 USD |
| 9/18/2025 | 9.65 USD |
| 9/17/2025 | 9.17 USD |
| 9/16/2025 | 9.11 USD |
| 9/15/2025 | 9.31 USD |
| 9/12/2025 | 9.74 USD |
| 9/11/2025 | 10.00 USD |
| 9/10/2025 | 9.63 USD |
| 9/9/2025 | 9.80 USD |
| 9/8/2025 | 9.81 USD |
| 9/5/2025 | 9.67 USD |
| 9/4/2025 | 9.83 USD |
| 9/3/2025 | 9.68 USD |
| 9/2/2025 | 9.61 USD |
| 8/29/2025 | 9.86 USD |
| 8/28/2025 | 9.74 USD |
| 8/27/2025 | 9.55 USD |
| 8/26/2025 | 9.90 USD |
| 8/25/2025 | 9.85 USD |
| 8/22/2025 | 10.10 USD |
| 8/21/2025 | 9.98 USD |
| 8/20/2025 | 9.84 USD |
| 8/19/2025 | 9.65 USD |
| 8/18/2025 | 9.75 USD |
| 8/15/2025 | 9.49 USD |
| 8/14/2025 | 9.35 USD |
| 8/13/2025 | 9.67 USD |
| 8/12/2025 | 9.56 USD |
| 8/11/2025 | 9.38 USD |
| 8/8/2025 | 9.20 USD |
| 8/7/2025 | 8.99 USD |
| 8/6/2025 | 8.91 USD |
| 8/5/2025 | 8.87 USD |
Exagen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Exagen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 17.00 | 26.00 | 32.00 | 40.00 | 41.00 | 48.00 | 45.00 | 52.00 | 55.00 | 66.00 | 71.00 | 79.00 | 89.00 | 101.00 | 105.00 |
| 266.67 | 54.55 | 52.94 | 23.08 | 25.00 | 2.50 | 17.07 | -6.25 | 15.56 | 5.77 | 20.00 | 7.58 | 11.27 | 12.66 | 13.48 | 3.96 |
| 36.36 | 47.06 | 46.15 | 53.13 | 52.50 | 60.98 | 56.25 | 46.67 | 55.77 | 60.00 | 57.58 | 57.58 | 57.58 | 57.58 | 57.58 | 57.58 |
| 4.00 | 8.00 | 12.00 | 17.00 | 21.00 | 25.00 | 27.00 | 21.00 | 29.00 | 33.00 | 38.00 | 40.88 | 45.48 | 51.24 | 58.15 | 60.45 |
| -11.00 | -10.00 | -7.00 | -5.00 | -9.00 | -14.00 | -24.00 | -45.00 | -22.00 | -13.00 | -15.00 | -33.00 | -37.00 | -42.00 | -47.00 | -50.00 |
| -100.00 | -58.82 | -26.92 | -15.63 | -22.50 | -34.15 | -50.00 | -100.00 | -42.31 | -23.64 | -22.73 | -46.48 | -46.84 | -47.19 | -46.53 | -47.62 |
| -14.00 | -19.00 | -25.00 | -8.00 | -12.00 | -16.00 | -26.00 | -47.00 | -23.00 | -15.00 | -19.00 | -12.00 | -9.00 | -6.00 | -2.00 | -2.00 |
| 7.69 | 35.71 | 31.58 | -68.00 | 50.00 | 33.33 | 62.50 | 80.77 | -51.06 | -34.78 | 26.67 | -36.84 | -25.00 | -33.33 | -66.67 | – |
| 0.06 | 0.06 | 21.56 | 0.06 | 12.56 | 12.65 | 16.97 | 17.19 | 17.84 | 18.20 | 21.56 | 21.56 | 21.56 | 21.56 | 21.56 | 21.56 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Exagen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Exagen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Exagen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Exagen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Exagen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Exagen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Exagen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Exagen business model & stock analysis
Exagen SWOT Analysis
Strengths
Exagen Inc has several strengths that contribute to its success in the market. One major strength is its advanced technology and innovative approach to diagnostic testing. This allows the company to provide accurate and reliable results, which in turn enhances its reputation and customer trust. Additionally, Exagen Inc has a strong team of skilled professionals who are experts in their respective fields, enabling the company to deliver high-quality services.
Weaknesses
Despite its strengths, Exagen Inc also faces certain weaknesses that need to be addressed. One weakness is its limited market presence, particularly in certain geographical regions. Expanding into these untapped markets could lead to increased growth opportunities. Moreover, Exagen Inc may face challenges in differentiating its offerings from competitors, as the diagnostic testing industry is highly competitive and constantly evolving.
Opportunities
Exagen Inc has various opportunities to capitalize on in order to further its success. The increasing demand for personalized medicine and precision diagnostics presents a significant opportunity for the company. By aligning its services with these emerging trends, Exagen Inc can attract new customers and gain a competitive edge. Furthermore, strategic partnerships with healthcare providers and research institutions can help Exagen Inc expand its reach and develop new diagnostic products.
Threats
Exagen Inc operates in an industry that is subject to certain threats, which must be carefully managed. One threat is the potential for regulatory changes and compliance requirements, which can impact the company's operations and increase costs. Additionally, the presence of new entrants and established competitors in the market poses a threat to Exagen Inc's market share. Staying vigilant and continuously innovating will be crucial to maintaining a competitive position in the industry.
Exagen Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Exagen Segments
Exagen Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Exagen Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
Exagen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Exagen historical P/E ratio, EBIT multiple, and P/S ratio
Exagen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Exagen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Exagen forecasts and price targets in August 2026
Analyst Price Targets 2026Exagen Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/12/2026 | Maintained | Buy | – | |
| 4/20/2026 | Maintained | Buy | 59 | |
| 3/11/2026 | Maintained | Overweight | 49 | |
| 3/11/2026 | Maintained | Buy | – | |
| 3/11/2026 | Maintained | Buy | 59 | |
| 3/10/2026 | Maintained | Buy | – | |
| 2/24/2026 | Maintained | Buy | 60 | |
| 2/17/2026 | Maintained | Buy | – | |
| 1/30/2026 | Maintained | Buy | – | |
| 11/10/2025 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Exagen Earnings Calls
Exagen Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/10/2026 | -0.19USD | - | 18.00 MUSD | - | 2026 Q2 |
| 5/12/2026 | -0.24USD | - | 16.58 MUSD | - | 2026 Q1 |
| 3/10/2026 | -0.19USD | - | 16.84 MUSD | - | 2025 Q4 |
| 11/12/2024 | -0.29USD | - | 13.70 MUSD | - | 2024 Q3 |
| 5/13/2024 | -0.43USD | - | 11.20 MUSD | - | 2024 Q1 |
| 3/18/2024 | -0.45USD | - | 11.80 MUSD | - | 2023 Q4 |
| 11/13/2023 | -0.66USD | - | 13.83 MUSD | - | 2023 Q3 |
| 8/2/2023 | -0.67USD | - | 12.30 MUSD | - | 2023 Q2 |
| 5/9/2023 | -0.76USD | - | 9.71 MUSD | - | 2023 Q1 |
| 3/20/2023 | -0.72USD | - | 9.77 MUSD | - | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Exagen stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Exagen shareholder structure
| % | Name |
|---|---|
3.70923% | |
1.84628% | |
0.51284% | |
0.42900% | |
0.31599% | |
0.15946% |
Exagen Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
17.00% | SEC ↗ | |
14.28% | SEC ↗ | |
13.40% | SEC ↗ | |
13.40% | SEC ↗ | |
13.40% | SEC ↗ | |
13.40% | SEC ↗ | |
11.80% | SEC ↗ | |
11.80% | SEC ↗ | |
11.80% | SEC ↗ | |
11.80% | SEC ↗ |
Exagen Executives and Management Board
9 members · avg. age 58 · 22 % women
Mr. John Aballi (40)
President, Chief Executive Officer, Director · since 2022
1.18 M USD
Management
Mr. Jeffrey Black (56)
Chief Financial Officer, Corporate Secretary
Board of Directors
Dr. Tina Nova (71)
Executive Chairman of the Board · since 2019
Ms. Ana Hooker (59)
Independent Director
Mr. Paul Kim (57)
Independent Director
Mr. Frank Stokes (55)
Independent Director
Dr. Scott Kahn (65)
Independent Director
Dr. Bruce Robertson (62)
Independent Director
Frequently asked questions about Exagen
The business model of Exagen Inc is focused on providing innovative and personalized diagnostic solutions for rheumatologists and patients. Exagen's products and services aim to aid in the diagnosis, prognosis, and monitoring of autoimmune diseases like lupus and rheumatoid arthritis. The company utilizes advanced technologies and proprietary algorithms to analyze patient samples and deliver accurate test results. Exagen's diagnostic approach enables healthcare professionals to make informed treatment decisions, optimize patient care, and potentially improve outcomes. With a strong dedication to advancements in autoimmune diagnostics, Exagen Inc strives to enhance the standard of care for patients with rheumatic diseases.
Exagen Inc is primarily active in the healthcare and diagnostics industries.
The main competitors of Exagen Inc in the market include companies such as Myriad Genetics, Genomic Health, Veracyte, and Exact Sciences.
Exagen Inc is a leading biotechnology company specializing in the development and commercialization of innovative diagnostic tests. Founded in 2002, Exagen focuses on empowering patients and improving the quality of care through cutting-edge technologies. The company is dedicated to transforming the diagnosis and management of complex diseases by providing healthcare professionals with actionable insights based on advanced genomic and proteomic analysis. With a strong commitment to research and development, Exagen continues to expand its portfolio of diagnostic tools, aiming to address unmet medical needs and revolutionize personalized medicine. With its rich history and expertise in molecular diagnostics, Exagen Inc has established itself as a trusted provider of innovative diagnostic solutions in the healthcare industry.
Exagen Inc has achieved several significant milestones. The company successfully launched its flagship product, AVISE CTD, a comprehensive diagnostic test for autoimmune connective tissue diseases. Exagen Inc also expanded its product portfolio with the addition of AVISE Lupus, a diagnostic test for systemic lupus erythematosus. Furthermore, the company received ISO 13485:2016 certification, demonstrating its commitment to quality management systems. Exagen Inc's advancements in precision medicine and dedication to improving patient outcomes have positioned the company as a leader in the field.
Exagen Inc is primarily present in the United States.
Exagen Inc represents values of innovation, excellence, and patient-centricity. With a commitment to advancing precision medicine, Exagen Inc focuses on transforming the care of patients by providing solutions for complex autoimmune diseases. Their corporate philosophy revolves around developing and commercializing diagnostic tests that empower physicians to deliver personalized treatment plans. Exagen Inc leverages cutting-edge technology and scientific expertise to improve patient outcomes and enhance the overall healthcare experience. By continuously investing in research and development, Exagen Inc aims to revolutionize the diagnosis and management of autoimmune diseases, making a positive impact on the lives of individuals worldwide.
Analysts currently set an average price target of 13.55 USD for the Exagen stock (median: 15.30 USD), implying +122.5 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Exagen stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Exagen to generate revenue of 71.59 M USD and earnings per share of -0.58 USD.
Converted at the current exchange rate, the Exagen share trades at 3.94 EUR (4.53 USD).
The Exagen share (XGN) is listed on 3 stock exchanges, including: NASDAQ (XGN), Frankfurt (E08A.F), München (E08A.MU).
Exagen Inc is an innovative provider of diagnostic tools and services to support clinics and research institutions in personalizing treatment plans for patients with autoimmune diseases. The company's business model is based on providing top-notch diagnostic solutions and interacting with professionals to ensure optimal patient treatment. The company specializes in the development, manufacturing, and distribution of diagnostic tests to support treatment plans for autoimmune diseases. The tests aim to serve both clinical and scientific purposes by delivering fast, accurate, and predictable results. The company's focus is on expanding the currently limited availability of tests for autoimmune diseases to enable personalized treatment plans for patients. One important area for Exagen Inc is the Clinical Research division. The company offers a range of diagnostic solutions for clinical studies to meet the need for personalized treatment options for patients with autoimmune diseases. The diagnostic tests in clinical studies are based on a thorough analysis of biomarkers characteristic of the disease. Another crucial segment for Exagen Inc is the individual diagnostics segment. The company offers its customers personalized diagnostic solutions for autoimmune diseases to enable tailored treatment for patients. The customizable solutions for autoimmune diseases aim to reduce the burden on patients by performing the appropriate tests, such as lupus, rheumatoid arthritis, or Sjögren's syndrome, for an accurate diagnosis. As part of its business model, Exagen Inc also collaborates with other companies to expand its portfolio of diagnostic solutions. The company maintains relationships with leading research centers and clinics to gain and share valuable insights from practice. Through this collaboration, the company can minimize risks and identify innovative partners. Exagen Inc is constantly striving to expand its range of diagnostic solutions for autoimmune diseases and stay up to date with the latest research in personalized medicine. The company aims to provide patients with autoimmune diseases with fast and accurate diagnoses, as well as suggest personalized treatment options. The company's business model offers an optimized approach to personalized treatment plans and better quality of life for patients with autoimmune diseases. The translation is provided as follows: Exagen Inc is an innovative provider of diagnostic tools and services to support clinics and research institutions in personalizing treatment plans for patients with autoimmune diseases.
The expected revenue of Exagen is 71.59 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Exagen is -12.56 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Exagen is currently -7.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Exagen stock.
The price-to-sales ratio (P/S) of Exagen is currently 1.36. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Exagen stock.
The Eulerpool Quality Score for Exagen is 4/10.
The ISIN of Exagen is US30068X1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Exagen is A2PRXT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Exagen is XGN. The ticker symbol is used to trade Exagen shares on the stock exchange.
Exagen paid dividends every year for the past 0 years.
Exagen is assigned to the 'Health' sector.
The dividends of Exagen are distributed in USD.
Exagen stock
Exagen Peer Group
Exagen Ticker
Exagen FIGI
All fundamentals and in-depth analysis of Exagen
Our stock analysis for Exagen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exagen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.